Market Closed -
Nasdaq
04:00:00 2024-05-28 pm EDT
|
5-day change
|
1st Jan Change
|
5.24
USD
|
-0.76%
|
|
-11.93%
|
-62.41%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,776
|
1,192
|
1,121
|
443.3
|
-
|
-
|
Enterprise Value (EV)
1 |
1,416
|
637.2
|
497.2
|
-8.529
|
215.7
|
443.3
|
P/E ratio
|
-8.23
x
|
-6.65
x
|
-4.47
x
|
-1.96
x
|
-1.84
x
|
-1.88
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
614
x
|
95.3
x
|
29.1
x
|
39
x
|
21.6
x
|
EV / Revenue
|
-
|
328
x
|
42.3
x
|
-0.56
x
|
19
x
|
21.6
x
|
EV / EBITDA
|
-16.6
x
|
-3.91
x
|
-2.28
x
|
0.03
x
|
-0.68
x
|
-1.18
x
|
EV / FCF
|
-17.2
x
|
-4.7
x
|
-3.28
x
|
0.04
x
|
-0.94
x
|
-1.92
x
|
FCF Yield
|
-5.81%
|
-21.3%
|
-30.5%
|
2,487%
|
-106%
|
-52.1%
|
Price to Book
|
2.77
x
|
1.9
x
|
1.49
x
|
1.2
x
|
1.47
x
|
1.62
x
|
Nbr of stocks (in thousands)
|
48,171
|
61,604
|
80,424
|
83,965
|
-
|
-
|
Reference price
2 |
36.87
|
19.35
|
13.94
|
5.240
|
5.240
|
5.240
|
Announcement Date
|
3/14/22
|
3/2/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
1.941
|
11.76
|
15.25
|
11.36
|
20.52
|
EBITDA
1 |
-
|
-85.53
|
-162.9
|
-217.7
|
-258.1
|
-319.4
|
-376.6
|
EBIT
1 |
-
|
-87.07
|
-165.7
|
-223.1
|
-240.3
|
-273.4
|
-296.9
|
Operating Margin
|
-
|
-
|
-8,536.17%
|
-1,897.64%
|
-1,575.8%
|
-2,406.03%
|
-1,446.85%
|
Earnings before Tax (EBT)
1 |
-
|
-120.3
|
-157.3
|
-199.8
|
-219.6
|
-253.6
|
-267.8
|
Net income
1 |
-45.7
|
-120.3
|
-157.4
|
-200.1
|
-224.2
|
-260.5
|
-283.3
|
Net margin
|
-
|
-
|
-8,108.55%
|
-1,701.55%
|
-1,469.86%
|
-2,292.45%
|
-1,380.38%
|
EPS
2 |
-
|
-4.480
|
-2.910
|
-3.120
|
-2.677
|
-2.842
|
-2.794
|
Free Cash Flow
1 |
-
|
-82.24
|
-135.6
|
-151.7
|
-212.1
|
-229.6
|
-230.9
|
FCF margin
|
-
|
-
|
-6,984.23%
|
-1,290.47%
|
-1,390.61%
|
-2,020.24%
|
-1,125.24%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/28/21
|
3/14/22
|
3/2/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
0.929
|
1.012
|
1.404
|
2.093
|
3.117
|
5.143
|
5.695
|
2.711
|
2.256
|
5.978
|
1.5
|
1.5
|
EBITDA
1 |
-32.07
|
-
|
-
|
-43.14
|
-46.78
|
-
|
-
|
-50.86
|
-
|
-55.21
|
-65
|
-
|
-
|
-
|
-
|
EBIT
1 |
-32.54
|
-31.92
|
-42.19
|
-43.86
|
-47.71
|
-58.26
|
-58.58
|
-52.33
|
-53.95
|
-56.84
|
-61.23
|
-63.87
|
-62.36
|
-64.38
|
-65.5
|
Operating Margin
|
-
|
-
|
-
|
-4,721.21%
|
-4,714.33%
|
-4,149.5%
|
-2,799%
|
-1,678.99%
|
-1,048.98%
|
-998.14%
|
-2,258.83%
|
-2,831.87%
|
-1,043.25%
|
-4,291.67%
|
-4,366.67%
|
Earnings before Tax (EBT)
1 |
-31.34
|
-30.17
|
-40.95
|
-45.19
|
-41.03
|
-51.98
|
-53.81
|
-45.69
|
-48.32
|
-48.63
|
-56.96
|
-59.73
|
-57.85
|
-60.48
|
-62.82
|
Net income
1 |
-31.34
|
-30.17
|
-40.95
|
-45.19
|
-41.08
|
-51.98
|
-53.98
|
-45.76
|
-48.35
|
-48.74
|
-56.97
|
-59.74
|
-57.85
|
-60.53
|
-62.88
|
Net margin
|
-
|
-
|
-
|
-4,864.37%
|
-4,059.68%
|
-3,701.92%
|
-2,579.22%
|
-1,468.01%
|
-940.17%
|
-855.77%
|
-2,101.67%
|
-2,648.44%
|
-967.8%
|
-4,035.23%
|
-4,191.67%
|
EPS
2 |
-0.6500
|
-0.6200
|
-0.8400
|
-0.7900
|
-0.6700
|
-0.8400
|
-0.8700
|
-0.7200
|
-0.6900
|
-0.5900
|
-0.6820
|
-0.7124
|
-0.6844
|
-0.7067
|
-0.7133
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/14/22
|
5/10/22
|
8/9/22
|
11/7/22
|
3/2/23
|
5/15/23
|
8/10/23
|
11/7/23
|
2/27/24
|
5/8/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
360
|
555
|
624
|
452
|
228
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-82.2
|
-136
|
-152
|
-212
|
-230
|
-231
|
ROE (net income / shareholders' equity)
|
-
|
-82%
|
-34.7%
|
-34.8%
|
-53.4%
|
-86.8%
|
-95.7%
|
ROA (Net income/ Total Assets)
|
-
|
-52%
|
-29.6%
|
-27.9%
|
-44%
|
-75.1%
|
-86.3%
|
Assets
1 |
-
|
231.3
|
531.7
|
716.1
|
510
|
347
|
328.3
|
Book Value Per Share
2 |
-
|
13.30
|
10.20
|
9.340
|
4.370
|
3.570
|
3.230
|
Cash Flow per Share
|
-
|
-
|
-2.260
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
4.36
|
13.2
|
9.28
|
8.18
|
9.22
|
8.85
|
Capex / Sales
|
-
|
-
|
681.71%
|
78.95%
|
53.6%
|
81.14%
|
43.13%
|
Announcement Date
|
5/28/21
|
3/14/22
|
3/2/23
|
2/27/24
|
-
|
-
|
-
|
Last Close Price
5.28
USD Average target price
26.89
USD Spread / Average Target +409.26% Consensus |
1st Jan change
|
Capi.
|
---|
| -62.41% | 443M | | +54.05% | 63.85B | | -2.02% | 41.83B | | +40.01% | 40.47B | | -10.22% | 27.17B | | +13.42% | 26.52B | | -21.60% | 18.69B | | +2.89% | 12.73B | | +22.40% | 12.11B | | +27.49% | 12.07B |
Other Biotechnology & Medical Research
|